Expert Opinion
In our series of expert videos on chronic kidney disease (CKD), Professor Hiddo Heerspink, Professor Vlado Perkovic and Dr George Bakris highlight:
- The unmet needs and challenges in CKD, including underdiagnosis
- The need for early CKD diagnosis and CKD screening strategies
- The importance of managing comorbid conditions
- CKD treatment goals and treatment options
- Newly approved treatments for CKD, including SGLT2 inhibitors and mineralocorticoid receptor antagonists
In this section
Professor Hiddo Heerspink
Professor Hiddo Heerspink from the University Medical Centre Groningen in the Netherlands highlights key unmet needs and clinical challenges for chronic kidney disease (CKD) and describes the DAPA-CKD trial, which led to approval of dapagliflozin for treatment of diabetic and non-diabetic kidney disease.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Professor Vlado Perkovic
Professor Vlado Perkovic from the University of New South Wales in Australia discusses the burden of chronic kidney disease (CKD), management of comorbid conditions and the addition of canagliflozin to the treatment armamentarium for diabetic kidney disease following the CREDENCE trial.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Dr George Bakris
Dr George Bakris from the University of Chicago Medicine in the US outlines the priorities for managing chronic kidney disease and how new treatments, including finerenone, evaluated in the FIDELIO-DKD trial, can improve outcomes for patients with diabetic kidney disease.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
of interest
are looking at
saved
next event
Developed by EPG Health for Medthority. This content has been developed independently of the sponsors AstraZeneca, who have reviewed the content only for scientific accuracy. EPG Health received educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.